The effect of growth hormone-releasing peptide-2 (KP102) administration on plasma insulin-like growth factor (IGF)-1 and IGF-binding proteins in Holstein steers on different planes of nutrition.

Lee HG, Vega RA, Phung LT, Matsunaga N, Kuwayama H, Hidari H

Domestic animal endocrinology1 Apr 2000Cited by 6 (Europe PMC)

PMID10793269DOI10.1016/s0739-7240(00)00051-5PepBankPUB-10793269

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In growing Holstein steers on low and high feed intake, plasma GH increased after an intravenous bolus of KP102 on Day 1 and Day 6.
In plain wordsIn young cattle, KP102 injected into a vein raised GH in the blood on Day 1 and Day 6.
Peptide
GHRP-2
Outcome
IncreasePlasma GH after i.v. bolus KP102
Study
cattlen = 8
growing Holstein steers
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
12.5 microg/kg body weight/day · intravenous · 6 daysAs given in this study (cattle).
Source sentences
Summary
The concentration of plasma GH showed an increase after an i.v. bolus injection of KP102 on Day 1 and Day 6 in both the LI and HI groups.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight 13 month-old Holstein steers were grouped on two levels of feed intake (high intake (HI); 2.43% body weight or low intake (LI); 1.22%) and each group was daily injected with KP102 (12.5 microg/kg body weight/day) or saline solution into the jugular vein during 6-day period.
Report a problemFND-1079326901
02AnimalAnimal study (in vivo)Efficacy outcome
In steers on high feed intake, plasma IGF-1 began to increase 10 hr after an intravenous bolus of KP102.
In plain wordsIn cattle fed a high amount of feed, KP102 raised IGF-1 in the blood.
Peptide
GHRP-2
Outcome
IncreasePlasma IGF-1 in high-intake steers
Study
cattlen: not reported in source
growing Holstein steers
Comparator
Saline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
12.5 microg/kg body weight/day · intravenous · 6 daysAs given in this study (cattle).
Source sentences
Summary
Plasma IGF-1 began to increase 10 hr following an i.v. bolus injection of KP102, but this was only observed in the HI group (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Eight 13 month-old Holstein steers were grouped on two levels of feed intake (high intake (HI); 2.43% body weight or low intake (LI); 1.22%) and each group was daily injected with KP102 (12.5 microg/kg body weight/day) or saline solution into the jugular vein during 6-day period.
Report a problemFND-1079326902
03AnimalAnimal study (in vivo)Efficacy outcome
In steers on high feed intake, plasma IGF-1 reached a maximum of 125.1 ng/ml after Day 2 and returned to pre-injection levels after Day 4.
In plain wordsIn cattle fed a high amount of feed, IGF-1 peaked after Day 2 and returned to earlier levels after Day 4.
Peptide
GHRP-2
Outcome
IncreaseTime course of plasma IGF-1 in high-intake steers
Study
cattlen: not reported in source
growing Holstein steers
Comparator
Saline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
12.5 microg/kg body weight/day · intravenous · 6 daysAs given in this study (cattle).
Measurements
maximum plasma IGF-1
125.1 ng/ml
high-intake group, after Day 2
Source sentences
Summary
It reached maximum values of 125.1 +/- 7.6 ng/ml after Day 2, and returned to pre-injection levels after Day 4
1 context sentence(design, population, supporting numbers)
Summary · context
Eight 13 month-old Holstein steers were grouped on two levels of feed intake (high intake (HI); 2.43% body weight or low intake (LI); 1.22%) and each group was daily injected with KP102 (12.5 microg/kg body weight/day) or saline solution into the jugular vein during 6-day period.
Report a problemFND-1079326903
04AnimalAnimal study (in vivo)Efficacy outcome
In steers on low feed intake, KP102 caused no change in plasma IGF-1.
In plain wordsIn cattle fed a low amount of feed, KP102 did not change IGF-1 in the blood.
Peptide
GHRP-2
Outcome
No significant changePlasma IGF-1 in low-intake steers
Study
cattlen: not reported in source
growing Holstein steers
Comparator
Saline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
12.5 microg/kg body weight/day · intravenous · 6 daysAs given in this study (cattle).
Source sentences
Summary
however, no change in plasma IGF-1 was observed in LI with administration of KP102.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight 13 month-old Holstein steers were grouped on two levels of feed intake (high intake (HI); 2.43% body weight or low intake (LI); 1.22%) and each group was daily injected with KP102 (12.5 microg/kg body weight/day) or saline solution into the jugular vein during 6-day period.
Report a problemFND-1079326904
05AnimalAnimal study (in vivo)Efficacy outcome
In steers on high feed intake, plasma 38-43 kDa IGFBP-3 was significantly higher in KP102-treated steers.
In plain wordsIn cattle fed a high amount of feed, KP102 raised one IGF-binding protein in the blood.
Peptide
GHRP-2
Outcome
IncreasePlasma 38-43 kDa IGFBP-3 in high-intake steers
Study
cattlen: not reported in source
growing Holstein steers
Comparator
Saline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
12.5 microg/kg body weight/day · intravenous · 6 daysAs given in this study (cattle).
Source sentences
Summary
During 6 days of treatment, plasma 38-43 kDa IGFBP-3 and 24 kDa IGFBP-4 were significantly higher in KP102 treated steers but only in the HI group (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Eight 13 month-old Holstein steers were grouped on two levels of feed intake (high intake (HI); 2.43% body weight or low intake (LI); 1.22%) and each group was daily injected with KP102 (12.5 microg/kg body weight/day) or saline solution into the jugular vein during 6-day period.
Report a problemFND-1079326905
06AnimalAnimal study (in vivo)Efficacy outcome
In steers on high feed intake, plasma 24 kDa IGFBP-4 was significantly higher in KP102-treated steers.
In plain wordsIn cattle fed a high amount of feed, KP102 raised another IGF-binding protein in the blood.
Peptide
GHRP-2
Outcome
IncreasePlasma 24 kDa IGFBP-4 in high-intake steers
Study
cattlen: not reported in source
growing Holstein steers
Comparator
Saline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
12.5 microg/kg body weight/day · intravenous · 6 daysAs given in this study (cattle).
Source sentences
Summary
During 6 days of treatment, plasma 38-43 kDa IGFBP-3 and 24 kDa IGFBP-4 were significantly higher in KP102 treated steers but only in the HI group (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Eight 13 month-old Holstein steers were grouped on two levels of feed intake (high intake (HI); 2.43% body weight or low intake (LI); 1.22%) and each group was daily injected with KP102 (12.5 microg/kg body weight/day) or saline solution into the jugular vein during 6-day period.
Report a problemFND-1079326906
07AnimalAnimal study (in vivo)Efficacy outcome
Plasma 34 kDa IGFBP-2 decreased in the high-intake group and did not change following a KP102 injection.
In plain wordsIn cattle, KP102 did not change the level of one IGF-binding protein in the blood.
Peptide
GHRP-2
Outcome
No significant changePlasma 34 kDa IGFBP-2
Study
cattlen: not reported in source
growing Holstein steers
Comparator
Saline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
12.5 microg/kg body weight/day · intravenous · 6 daysAs given in this study (cattle).
Source sentences
Summary
Plasma 34 kDa IGFBP-2 decreased in the HI group and did not show any change following an injection of KP102.
1 context sentence(design, population, supporting numbers)
Summary · context
Eight 13 month-old Holstein steers were grouped on two levels of feed intake (high intake (HI); 2.43% body weight or low intake (LI); 1.22%) and each group was daily injected with KP102 (12.5 microg/kg body weight/day) or saline solution into the jugular vein during 6-day period.
Report a problemFND-1079326907
08AnimalAnimal study (in vivo)Efficacy outcome
In growing Holstein steers given daily KP102, plasma IGF-1 in the high-intake group was significantly greater than in the low-intake group from Day 1.
In plain wordsIn young cattle given daily KP102, blood IGF-1 was higher in those fed a high amount of feed than in those fed a low amount.
Peptide
GHRP-2
Outcome
IncreasePlasma IGF-1 in high-intake versus low-intake steers
Study
cattlen: not reported in source
growing Holstein steers
Comparator
Low-intake group
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
12.5 microg/kg body weight/day · intravenous · 6 daysAs given in this study (cattle).
Source sentences
Summary
Also, the plasma IGF-1 in the HI group with daily injections was significantly greater than the LI group from Day 1 of KP102 administration (P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Eight 13 month-old Holstein steers were grouped on two levels of feed intake (high intake (HI); 2.43% body weight or low intake (LI); 1.22%) and each group was daily injected with KP102 (12.5 microg/kg body weight/day) or saline solution into the jugular vein during 6-day period.
Report a problemFND-1079326908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.